Bio

I’m originally from Birmingham, AL. I completed my undergraduate education at Tuskegee University and majored in Biology/Pre-Health and minored in Bioethics. I also received a Master of Science in Biomedical & Health Sciences from the University of Alabama at Birmingham and completed medical school at the University of South Alabama College of Medicine. Following graduation from medical school, my intern year was spent in my hometown at Brookwood Baptist Health Transitional Year Program. One of my favorite aspects of radiation oncology at Stanford is the opportunity to give compassionate medical care to our cancer patients while working with the latest state-of-the-art medical technology. In my free time I enjoy playing tennis, exercising, traveling, trying new restaurants, and spending time with my family & friends.

Clinical Focus

  • Residency
  • Radiation Oncology

Boards, Advisory Committees, Professional Organizations

  • Chair, Association of Residents in Radiation Oncology (2024 - Present)
  • Executive Co-Chair, Stanford Medicine GME Diversity Committee (2023 - Present)

Professional Education

  • Internship, Brookwood Baptist Health, Transitional Year (2022)
  • MD, University of South Alabama College of Medicine (2021)
  • MS, University of Alabama at Birmingham, Biomedical and Health Sciences (2016)
  • BS, Tuskegee University, Biology/Pre-Med (2015)

All Publications

  • The role of annexins in central nervous system development and disease. Journal of molecular medicine (Berlin, Germany) White, Z. B., Nair, S., Bredel, M. 2024

    Abstract

    Annexins, a group of Ca2+-dependent phospholipid-binding proteins, exert diverse roles in neuronal development, normal central nervous system (CNS) functioning, neurological disorders, and CNS tumors. This paper reviews the roles of individual annexins (A1-A13) in these contexts. Annexins possess unique structural and functional features, such as Ca2+-dependent binding to phospholipids, participating in membrane organization, and modulating cell signaling. They are implicated in various CNS processes, including endocytosis, exocytosis, and stabilization of plasma membranes. Annexins exhibit dynamic roles in neuronal development, influencing differentiation, proliferation, and synaptic formation in CNS tissues. Notably, annexins such as ANXA1 and ANXA2 play roles in apoptosis and blood-brain barrier (BBB) integrity. Neurological disorders, including Alzheimer's disease, multiple sclerosis, and depression, involve annexin dysregulation, influencing neuroinflammation, blood-brain barrier integrity, and stress responses. Moreover, annexins contribute to the pathogenesis of CNS tumors, either promoting or suppressing tumor growth, angiogenesis, and invasion. Annexin expression patterns vary across different CNS tumor types, providing potential prognostic markers and therapeutic targets. This review underscores the multifaceted roles of annexins in the CNS, highlighting their importance in normal functioning, disease progression, and potential therapeutic interventions.

    View details for DOI 10.1007/s00109-024-02443-7

    View details for PubMedID 38639785

    View details for PubMedCentralID 3436854

  • The adherence to the American Association for the Study of Liver Diseases 2018 guidelines in the management of hepatocellular carcinoma and its impact on survival. Journal of cancer research and therapeutics Manne, A., Mulekar, M., Escobar, D., Prodduturvar, P., Fahmawi, Y., Henderson, P., Abdul-Rahim, O., Hussain, Z., Liles, S., Fonseca, A., Howard, J. H., Mneimneh, W., Gilbert, R., Alkharabsheh, O., Pai, S., White, Z. B., Nelson, C., Khushman, M. 2023; 19 (5): 1103-1108

    Abstract

    In two Korean and Italian studies, the adherence rate (AR) to ASSLD 2005 guidelines in the management of hepatocellular carcinoma (HCC) was 60%. In a US study, the AR to American Association for the Study of Liver Disease (AASLD) 2005 guidelines was 73.3%, 26.8%, 25.3%, and 58.8% for patients with Barcelona Clinic Liver Cancer (BCLC) Stage A, B, C, and D, respectively, and nonadherence to guidelines was associated with longer overall survival (OS) in patients with BCLC Stage D. Here, we explored the AR to AASLD 2018 guidelines and its impact on OS.Between 2017 and 2019, 148 unique treatment-naïve patients with HCC were identified. Patients were staged according to the BCLC staging system and their AR to AASLD 2018 guidelines was noted. OS was estimated using Kaplan-Meier method. Survivals among patients from different groups was compared using Log-rank test.The overall AR to AASLD 2018 guidelines was 83%. The AR for BCLC Stages 0, A, B, C, and D were 100%, 97%, 77%, 77%, and 38%, respectively. In patients with BCLC Stage D, the OS of patients treated with modalities adherent versus nonadherent to AASLD 2018 guidelines was 0.03 vs. 5.2 months (P = 0.0005). Otherwise, adherence versus nonadherence to AASLD 2018 guidelines showed no statistically significant differences in OS for patients with BCLC Stages 0, A, B, and C.The overall AR to AASLD 2018 guidelines was 83%. Nonadherence to AASLD 2018 guidelines in patients with BCLC Stage D translated into better OS.

    View details for DOI 10.4103/jcrt.jcrt_1861_20

    View details for PubMedID 37787270

  • Analysis of the Association of Residents in Radiation Oncology Equity and Inclusion Subcommittee (ARRO EISC) Black History Month (BHM) Campaign: Moving Beyond Awareness Ewongwo, A., Pereira, I., White, Z., LeCompte, M., Washington, C., Bajaj, A., Sim, A., Vidal, G., Franco, I. ELSEVIER SCIENCE INC. 2022: E16-E17

    View details for Web of Science ID 000841321300031

  • Longitudinal Analysis of a Social Media Campaign to Increase Awareness and Engagement Among Radiation Oncologists for Black History Month (BHM) Ewongwo, A., Pereira, I., White, Z., LeCompte, M., Washington, C., Taparra, K., Ponce, S., Elbanna, M., Bajaj, A., Sim, A., Balogun, O., Rivera, A., Chaurasia, A., Vidal, G., Franco, I. LIPPINCOTT WILLIAMS & WILKINS. 2022: S46-S47

    View details for Web of Science ID 000847787800099

  • Effect of Terminology Used to Describe Medical Oncologists on Perceptions of Radiation Oncologists as Equal Partners in Cancer Care. Advances in radiation oncology Mattes, M. D., White, Z., Golden, D. W., Vapiwala, N., Herman, J. M., Royce, T. J. 2021; 6 (1): 100560

    Abstract

    Our purpose was to assess the terminology used to describe the different oncologic subspecialties at academic institutions in the United States and determine whether the use of the term "oncologist" to describe a medical oncologist (MO) may affect the multidisciplinary care of patients with cancer.An electronic survey was sent to chairs and program directors at all 94 academic radiation oncology departments in the United States. Questions assessed the terminology used to describe the oncologic subspecialties in their hospital's electronic medical record system, their views on how that terminology may affect referral patterns, and the perception of radiation oncologists' (ROs) role in patient care.Responses were received from 40 institutions (response rate, 42.6%). Fifteen percent of hospital electronic medical record systems used the term "oncology" instead of "medical oncology" (51%) or "hematology/oncology" (28%). Describing MOs simply as "oncologists" was thought to more likely affect patient views of MOs as the primary decision maker in their cancer care (mean Likert-type rating, 3.43) than it would affect the probability of up-front multidisciplinary referrals (mean Likert-type rating, 2.69). Patient perceptions of ROs as equal partners in care were thought to be less associated with the terminology used to describe MOs (mean Likert-type rating, 3.15) than the behavior of ROs in patient care (mean Likert-type rating, 4.65; P < .001), the attitude of MOs toward ROs (mean Likert-type rating, 4.59; P < .001), and the involvement of ROs in the initial new patient visits rather than a downstream referral (mean Likert-type rating, 3.95; P < .001).The terminology used to describe MOs was thought to affect patient and provider perceptions of RO, but less so than other patient-provider interaction factors.

    View details for DOI 10.1016/j.adro.2020.09.001

    View details for PubMedID 33869897

    View details for PubMedCentralID PMC8042774

  • Impact of ANXA7 I1 Expression on PDGFRA and MET Endosomal Trafficking in Glioblastoma White, Z. B., Dates, C., Rajbhandari, R., Nair, S., Nozell, S., Bredel, M. ELSEVIER SCIENCE INC. 2019: E683

    View details for DOI 10.1016/j.ijrobp.2019.06.1009

    View details for Web of Science ID 000485671502111